EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma

Yuchao He, Linlin Zhan, Jian Shi, Manyu Xiao, Ran Zuo, Chengmeng Wang, Zhiyong Liu, Wenchen Gong, Liwei Chen, Yi Luo, Shaojun Zhang, Youwei Wang und 2 weitere

Advanced Science · 2023

DOI: 10.1002/advs.202207650 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Yuchao He und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Tianjin, Tianjin Health Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel promising strategies for combination with sorafenib are urgently needed to enhance its clinical benefit and overcome toxicity in hepatocellular carcinoma (HCC). the molecular and immunomodulatory antitumor effects of sorafenib alone and in combination with the new immunotherapeutic agent R848 are presented. Syngeneic HCC mouse model is presented to explore the antitumor effect and safety of three sorafenib doses alone, R848 alone, or their combination in vivo. R848 significantly enhances the sorafenib antitumor activity at a low subclinical dose with no obvious toxic side effects. Furthermore, the combination therapy reprograms the tumor immune microenvironment by increasing antitumor macrophages and neutrophils and preventing immunosuppressive signaling. Combination treatment promotes classical M1 macrophage‐to‐FTH1 high M1 macrophage transition. The close interaction between neutrophils/classical M1 macrophages and dendritic cells promotes tumor antigen presentation to T cells, inducing cytotoxic CD8 + T cell‐mediated antitumor immunity. Additionally, low‐dose sorafenib, alone or combined with R848, normalizes the tumor vasculature, generating a positive feedback loop to support the antitumor immune environment. Therefore, the combination therapy reprograms the HCC immune microenvironment and normalizes the vasculature, improving the therapeutic benefit of low‐dose sorafenib and minimizing toxicity, suggesting a promising novel immunotherapy (R848) and targeted therapy (tyrosine kinase inhibitors) combination strategy for HCC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAnimalsMiceSorafenibPhenylurea CompoundsNiacinamideTumor Microenvironment

Stichwörter der Autor:innen

R848hepatocellular carcinomaimmune microenvironmentsorafenibvascular normalization

Substanzen

SorafenibPhenylurea CompoundsNiacinamide

Autor:innen und Institutionen

  • Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
  • National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
  • Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
  • School of Pharmacy, Minzu University of China, Beijing, 10081, China.
  • Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
  • Medical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.

ORCID-Profile: Hua Guo

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Tianjin
  • Tianjin Health Science and Technology Project
  • Natural Science Foundation of Tianjin City

Zitieren

APA

He, Y., Zhan, L., Shi, J., Xiao, M., Zuo, R., Wang, C., Liu, Z., Gong, W., Chen, L., Luo, Y., Zhang, S., Wang, Y., Chen, L., & Guo, H. (2023). The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202207650

Vancouver

He Y, Zhan L, Shi J, Xiao M, Zuo R, Wang C, et al. The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma. Advanced Science. 2023. doi:10.1002/advs.202207650

BibTeX
@article{He2023,
  author = {He, Yuchao and Zhan, Linlin and Shi, Jian and Xiao, Manyu and Zuo, Ran and Wang, Chengmeng and Liu, Zhiyong and Gong, Wenchen and Chen, Liwei and Luo, Yi and Zhang, Shaojun and Wang, Youwei and Chen, Lu and Guo, Hua},
  title = {The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma},
  journal = {Advanced Science},
  year = {2023},
  doi = {10.1002/advs.202207650}
}
Kostenlos starten →